中文
中文

以患者需求为核心,驱动细胞免疫治疗创新,实现癌症可控化并最终治愈。

We strive to make patients-driven cellular immunotherapy innovation, to transform cancer into a manageable condition — and ultimately cure it.
 

Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy
  • 0


On the cover: 
The transdifferentiation paths of erythroid precursor cells (EPCs) under the influence of tumor is delineated from Palantir algorithm‐based single-cell transcriptomic trajectory analysis (Long et al., 674–693), and embedded into artwork inspired by Wassily Kandinsky's “Composition 8.” As acquired “organs,” tumors exert a self-beneficial influence on the immune system by hijacking of erythropoiesis for myelopoiesis. Besides exacerbating anemia, CD45+ EPCs transdifferentiation generates myeloid cells that robustly curtail anti‐tumor immunity. Clinically, the abundance of these converted cells predicts immune tolerance in many human tumor types and resistance to immune checkpoint inhibitor treatment. Design and painting by Yijie Hou. Conceptual visualization by Qi-Jing Li and Bo Zhu.

https://www.cell.com/cancer-cell/current#closeFullCover

 

Copyright © 2019 天科雅生物医药科技有限公司

粤公网安备 44011502000528号

粤ICP备20056630号 Powered by vancheer
关于天科雅
研究与发展
产品及临床
新闻与媒体

Copyright © 2019 天科雅生物医药科技有限公司

粤公网安备 44011502000528号

粤ICP备20056630号 Powered by vancheer